The global pharmaceutical market reached $1,737 billion in 2024, growing by over 8% year-on-year. According to IQVIA projections, this market could reach $2,400 billion by 2029, driven by an annual growth rate of 5 to 8%. Behind these aggregated figures, several structural movements are reshaping the pharmaceutical sector: massive patent expirations, the rise of biosimilars, shifts in therapeutic formats, and accelerated digitalization of production.
Revenue and Growth of the Global Pharmaceutical Market
The geographical concentration of the market remains striking. In 2024, ten countries accounted for nearly 74% of global revenue. France maintains its position in fifth place in the international ranking, but the gap with the North American and Chinese markets continues to widen.
See also : The latest must-know news for professionals and entrepreneurs in 2024
| Indicator | Value |
|---|---|
| Global Revenue 2024 | $1,737 billion |
| Growth 2024 vs 2023 | 8.09% |
| Rebound 2023 vs 2022 | 8.2% |
| Projection 2029 (IQVIA) | $2,400 billion |
| Projected Annual Growth | 5 to 8% |
| Share of Top 10 Markets | about 74% |
| France’s Rank | 5th globally |
This trajectory relies on two opposing dynamics. The arrival of biotechnology-derived treatments is redefining therapeutic standards and business models. Conversely, the loss of patents on a significant number of drugs exerts downward pressure on the revenues of established laboratories.
To keep track of these developments over time, recent articles on Pharmavia regularly cover key events in the sector in France and internationally.
Further reading : Discover all the latest news and updates in the world of classifieds
Patent Cliff: The Structural Risk for the Pharmaceutical Industry
The term “patent cliff” refers to the wave of expirations expected between 2025 and 2035. It concerns some of the best-selling molecules globally, with substantial cumulative sales. This phenomenon mechanically opens up space for generics and biosimilars but weakens the portfolios of major laboratories.
Most competing analyses address market growth without measuring the extent of this threat. The patent cliff is restructuring the R&D strategies of pharmaceutical groups, which must compensate for revenue losses through biotech acquisitions or therapeutic diversifications.
Biosimilars and Generics in France: New Regulatory Phase
In France, the “third-party payment for generics” system is set to be extended to biosimilars and hybrids starting in September 2026. This measure will concretely change the substitution and reimbursement pathways in pharmacies.
- Pharmacists will have an additional lever to direct dispensing towards biosimilars, with a direct impact on the penetration rate of these products
- Biosimilar laboratories will find it easier to access the French market, which could accelerate competition for biological molecules that have entered the public domain
- Patients will benefit from potentially reduced out-of-pocket costs, provided that price differences between biosimilars and references are maintained
This regulatory mechanism illustrates how public health policy supports the post-patent transition, beyond just market dynamics.
Anti-Obesity Treatments: The Shift to Oral Forms
The anti-obesity treatment market, previously dominated by GLP-1 type injections, is experiencing a strategic shift. Several major laboratories are accelerating the development of oral forms of anti-obesity medications, changing the game in terms of access, compliance, and commercial strategy.
The transition from injection to oral form reduces a major entry barrier for patients. The convenience of a daily pill, compared to a weekly injection, mechanically broadens the target population.
This transition also alters the competitive balance. Laboratories capable of offering an effective oral formulation will have a competitive advantage in a segment that remains among the fastest-growing in the pharmaceutical sector.
Digitalization and Artificial Intelligence in Pharmaceutical Production
The digitalization of pharmaceutical manufacturing is no longer limited to the automation of production lines. Artificial intelligence is now involved at several stages of the value chain, from molecular design to quality control and risk management for contamination.
- Optimizing manufacturing processes through algorithms reduces rejection rates and accelerates the scaling up of new molecules
- Digital traceability of batches enhances drug safety and meets the increasing serialization requirements imposed by European regulations
- Predictive tools applied to the supply chain allow for anticipating supply disruptions, a recurring issue since post-pandemic tensions
Artificial intelligence also accelerates preclinical phases by identifying promising drug candidates among millions of compounds. This computational screening capability reduces development timelines and costs, even though human clinical phases remain non-negotiable.
Sustainability and Packaging in the Pharmaceutical Industry
Sustainability is gaining ground in packaging and conditioning choices. Laboratories are rethinking their formats to reduce the carbon footprint of health products, under the combined pressure of environmental regulations and the expectations of hospital buyers.
Pharmaceutical packaging is evolving towards recyclable materials without compromising the safety or stability of the drug. This technical compromise remains one of the most concrete challenges of the ecological transition applied to the sector.
The pharmaceutical sector is undergoing a period where therapeutic innovation, regulatory pressure, and industrial transformation converge. The patent cliff and the rise of biosimilars are reshuffling the cards for the next decade, while oral anti-obesity forms and artificial intelligence are redefining the contours of competition among laboratories.